Target intelligence / Profile preview

Pathogenic gut bacterium

Molecular classification
Other (Bacteria; not a single molecular target)
01

Overview

"Pathogenic gut bacteria" is not a specific molecule or receptor but rather a broad term referring to various bacterial species in the gastrointestinal tract that can cause disease. These include well-known genera and species such as *Klebsiella pneumoniae*, *Bacteroides fragilis*, *Shigella* spp., *Salmonella* spp., and others[1][3]. Pathogenicity arises from their ability to invade host tissues, evade immune responses, and produce toxins that damage host cells or disrupt normal physiological processes[5]. While some are always pathogenic when present in the gut (*Shigella*, *Salmonella*), others may be part of the normal flora but become harmful under certain conditions (*Bacteroides fragilis*)[1][2]. Because "pathogenic gut bacteria" refers to a diverse group rather than a single entity or molecular target, it does not fit standard definitions for therapeutic targets like receptors or enzymes. Instead, it encompasses multiple organisms with varied mechanisms of pathogenesis and drug susceptibility profiles. Treatment typically involves antibiotics tailored to the specific pathogen involved; however, increasing antibiotic resistance among these organisms poses significant therapeutic challenges[4]. In summary: "Pathogenic gut bacterium" is an umbrella term for disease-causing bacterial species in the gastrointestinal tract—not a singular molecular target—and should be replaced by more precise nomenclature when possible.

Other names
Pathogenic gut bacteriaHarmful gut bacteriaGut pathogensIntestinal pathogenic bacteria
02

Mechanism of action

Inhibition of bacterial cell wall synthesis (e.g., beta-lactams) - Inhibition of protein synthesis (e.g., macrolides)

03

Biological functions

InfectionImmune response modulationToxin production
04

Disease associations

InfectionInflammation
05

Safety considerations

Antibiotic resistance[4]
06

Interacting drugs

Antibiotics (e.g., ciprofloxacin, vancomycin, penicillin G)[3]

Beyond the preview

Go deeper on Pathogenic gut bacterium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pathogenic gut bacterium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call